Baxter Alzheimer's drug effective at 9 months: study
By Susan Kelly
CHICAGO (Reuters) - Alzheimer's disease patients treated with Baxter International Inc's Gammagard for nine months maintained cognitive function and in some cases improved it, according to an interim analysis of data from a small study.
"If successful, it should actually alter the long-term course of the illness, and the effects should persist for a very long time," Dr. Norman Relkin, lead researcher for the study and a neuroscientist at New York-Presbyterian Hospital/Weill Cornell Medical Center, said in an interview on Wednesday.
Gammagard, an intravenous therapy of antibodies derived from human plasma that has been sold for other uses for 15 years, is intended to attack the disease in two ways.
The antibodies target beta amyloid proteins thought to disrupt brain function in Alzheimer's patients. Gammagard also contains anti-inflammatory properties that may activate microglia cells to help dissolve amyloid deposits, or plaques.
(Additional reporting by Bill Berkrot in New York)
© Thomson Reuters 2009 All rights reserved
One Year Later
Mumbai held tearful memorials and police staged a show of strength as it marked the first anniversary of militant raids that killed 166 people and ratcheted up tensions with Pakistan. Slideshow | Full Coverage
Liberhan Commission Report
The government published a long awaited report, recently leaked, accusing BJP leaders of a role in the 1992 destruction of the Babri mosque in Ayodhya. Full Article
